Population under study: Patients with chronic obstructive pulmonary disease (COPD) who remain symptomatic (CAT=10) despite current treatment with dual long-acting bronchodilator therapy with LABA-LAMA, have suffered 1 moderate COPD exacerbation in the previous year (treated with oral corticosteroids and/or antibiotics), and have a blood eosinophil count =150 Eos/?L. A total of 1028 patients from 40 to 80 years old will be included.
Phase and design: Phase IV, open-label, prospective, pragmatic, interventional, randomized (1:1), multicenter, controlled, 12-month duration study.
Investigational drug: Trelegy®
Auxiliary medications: None
Primary objective: To determine the efficacy of Trelegy® vs. LABA-LAMA treatment in improving clinical control (CC), a validated composite endpoint that includes two domains, stability, and impact, in COPD B+ patients (as detailed below).
Primary endpoint: To determine the existence of an association between the use of Trelegy® vs. LABA-LAMA treatment with being a patient persistently controlled by CC at all study visits (a subject to be a categorize as having clinical control they must meet the criteria at month 3, 6, 9 and 12).

Objectives
Primary:
– To estimate the prevalence of reverse-transcription polymerase chain reaction (RT-PCR) confirmed RSV-ARI in participants, byseason, by country, by age group, by setting and
by RSV subtype (A/B).
Secondary
– To describe duration and symptoms/signs of ARI in participants with RT-PCR-confirmed RSV infection by season, by country, by age group, by setting, by RSV subtype (A/B) and overall.• Duration of ARI and occurrence of symptoms/signs of ARI in participants with RT-PCR-confirmed RSV
infection, during the 28 days after Visit 1 (until Day 29) if ARI resolves within 4 weeks or for 56 days after Visit 1 (until Day 57) if ARI has not resolved after 4 weeks.
– To describe underlying co-morbidities of participants with RT-PCR-confirmed RSV infection.
– Presence of co-morbidities (past, current and chronic) in participants with RT-PCR-confirmed RSV infection at Visit 1 (Day 1).

Evaluar la respuesta inmune basada en anticuerpos después de recibir una dosis única de revacunación de la vacuna RSVPreF3 OA en dos momentos distintos: antes de la temporada 4 (aproximadamente 36 meses después de recibir la dosis de vacuna en el estudio anterior) en el grupo VRS_PreT4, y antes de la temporada 5 (aproximadamente 48 meses después de la dosis de
vacuna recibida en el estudio anterior) en el grupo VRS_PreT5.

El objetivo principal es determinar la eficacia de la realización de pruebas rápidas de antígenos bivalentes (COVID-19 y gripe) en la reducción de la prescripción de antibióticos en pacientes de atención primaria con signos y/o síntomas de infección respiratoria

Investigación clínica prospectiva, multicéntrica, aleatorizada, controlada y a doble ciego para evaluar la seguridad y eficacia de una solución salina hipertónica con efecto descongestionante en adultos y niños mayores de 3 años que padecen congestión nasal secundaria a rinitis, rinosinusitis y rinofaringitis, afecciones ORL del periodo invernal, en comparación con la solución salina isotónica (solución salina fisiológica) utilizada habitualmente, con un seguimiento de 7 días.